List view / Grid view
Approval provides continuity of care into adulthood for patients with…
Approval provides continuity of care into adulthood for patients with neurofibromatosis type 1 (NF1) using Koselugo (selumetinib) to manage symptoms.
As part of the proposed acquisition, Alexion (AstraZeneca Rare Disease)…
As part of the proposed acquisition, Alexion (AstraZeneca Rare Disease) will add a therapeutic to its pipeline that has potential to “shift the treatment paradigm” in hypoparathyroidism.
Extended EU approval of Soliris to paediatric generalised myasthenia gravis…
Extended EU approval of Soliris to paediatric generalised myasthenia gravis (gMG) patients is based on Phase III data which demonstrated improvement in disease severity through 26 weeks.
The first and only long-acting C5 inhibitor, Ultomiris (ravulizumab), has…
The first and only long-acting C5 inhibitor, Ultomiris (ravulizumab), has been permitted in Europe for adults with generalised myasthenia gravis.
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323649599-300x278.jpg)
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323657672.jpg)
The investment in new drug substance production equipment and warehousing…
The investment in new drug substance production equipment and warehousing facilities to enhance Alexion’s biologics manufacturing in Ireland.
AstraZeneca today announced it has completed the purchase of Sumitomo…
26 March 2014 | By AstraZeneca
AstraZeneca today announced it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K...
"Following a thorough and extensive search it became clear that…
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
AstraZeneca announced that Marc Dunoyer is to join the company...
21 March 2013 | By AstraZeneca
AstraZeneca announced that Marc Dunoyer is to join the company...
Six-month primary treatment period results...
19 December 2012 | By GlaxoSmithKline
Six-month primary treatment period results...
Fabry products to be commercialised by Amicus in US and…
17 July 2012 | By GlaxoSmithKline
Fabry products to be commercialised by Amicus in US and by GSK ex-US...
